Evidence map›Paper›PMID 29049737›Full record

ArticleInvestigative ophthalmology & visual science2017

Introduction of the MDM2 T309G Mutation in Primary Human Retinal Epithelial Cells Enhances Experimental Proliferative Vitreoretinopathy.

Guohong Zhou, Yajiang Duan, Gaoen Ma, Wenyi Wu, Zhengping Hu, Na Chen, Yewlin Chee, Jing Cui, Arif Samad, Joanne A Matsubara and 3 more

Open access · goldAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. TheFrontiers in cell and developmental biology · 2022
    Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Guohong ZhouSchepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States.
Yajiang DuanSchepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States.
Gaoen MaSchepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States.
Wenyi WuSchepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States.
Zhengping HuSchepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States.
Na ChenSchepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States.
Yewlin CheeMassachusetts Eye and Ear Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States.
Jing CuiDepartment of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Arif SamadDalhousie University, Halifax, Nova Scotia, Canada.
Joanne A MatsubaraDepartment of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Shizuo MukaiMassachusetts Eye and Ear Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States.
Patricia A D'AmoreSchepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States.
Hetian LeiSchepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States.
Smith-Kettlewell Eye Research Institute · USMassachusetts Eye and Ear Infirmary · USHarvard University · USUniversity of British Columbia · CADalhousie University · CA

Funding

VISION RESEARCHP30EY003790 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Patricia Ann D'Amore · 1985 to 2026
$25.5M
PDGF and PVRR01EY012509 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI LEI, HETIAN · 2000 to 2017
$8.5M
NEI NIH HHS P30 EY003790NEI NIH HHS R01 EY012509
6 · The paper itself

Abstract

Purpose: The murine double minute (MDM)2 is a critical negative regulator of the p53 tumor suppressor, and MDM2 SNP309G is associated with a higher risk of proliferative vitreoretinopathy (PVR); in addition, the MDM2 T309G created using clustered regularly interspaced short palindromic repeats (CRISPR)/associated endonuclease (Cas)9 enhances normal rabbit vitreous-induced expression of MDM2 and survival of primary human retinal pigment epithelial (hRPE) cells in vitro. The goal of this study was to determine whether this MDM2 T309G contributes to the development of experimental PVR. Methods: hRPE cells expressing MDM2 T309G or T309T only were treated with vitreous from human PVR donors (HV). The expression of MDM2 and p53 in the treated cells was examined by Western blot. The in vitro vitreous-induced cellular responses, such as contraction were assessed, and PVR was induced by intravitreal injection of the hRPE cells with MDM2 T309G or T309T only into rabbit eyes. Results: Western blot analyses indicated that treatment of hRPE cells with HV led to a significant increase (1.7 ± 0.2-fold) in the expression of MDM2 and a significant decrease in p53 in the cells expressing MDM2 T309G compared with those with MDM2 T309T. In addition, HV promoted contraction of the hRPE cells expressing MDM2 T309G significantly more than those with MDM2 T309T only. Furthermore, MDM2 T309G in the hRPE cells enhanced the development of PVR in a rabbit model. Conclusions: The MDM2 SNP309 in RPE cells enhances their potential of PVR pathogenesis.

Indexed as

Disease Models, AnimalPolymorphism, Single NucleotideAnimalsApoptosisBlotting, WesternCell CountCell ProliferationCells, CulturedClustered Regularly Interspaced Short Palindromic RepeatsFemaleGene Expression RegulationHumansIntravitreal InjectionsMaleProto-Oncogene Proteins c-mdm2RabbitsMDM2 protein, humanProto-Oncogene Proteins c-mdm2RNA, MessengerTumor Suppressor Protein p53

Identifiers

PMID29049737
PMCPMC5649510
OpenAlexW2737522886

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.